BioAdaptives Inc. (OTC: BDPT) has announced the Institutional Review Board (IRB) approval for a human clinical trial of Zeranovia™, its weight management product. The trial, set to take place in Las Vegas, Nevada, will initially focus on confirming the appropriate dosage and monitoring potential side effects. The company aims to position Zeranovia as a natural alternative to synthetic GLP-1 and GIP treatments.
Trial Design and Objectives
The first phase of the clinical trial has already seen participant slots filled through website sign-ups, indicating strong initial interest. According to BioAdaptives, the trial is designed to rigorously assess Zeranovia's safety and efficacy. Subsequent phases will involve additional participants to further evaluate the product's weight management capabilities.
Zeranovia Composition and Rationale
Zeranovia is formulated as a high-protein blend that includes vitamins, minerals, and five herbal supplements, four of which are adaptogens. BioAdaptives believes this unique composition will yield results comparable to those achieved with synthetic GLP-1 and GIP treatments, which are commonly used in diabetes and weight management. The company highlights that less than 1.0% of nutraceuticals in the United States undergo human clinical trials, underscoring their commitment to scientific validation.
Management Commentary
"We are committed to supplying the highest quality products with provable scientific results," stated BioAdaptives CEO James Keener. He added that Zeranovia's success is based on its blend of vitamins, minerals, and concentrated herbal supplements. Keener's team dedicated nearly a year to product development, including extensive lab work, before moving Zeranovia to clinical trials. The company anticipates that the human clinical trials will mirror the positive results already observed during the development phase.
